Publications en collaboration avec des chercheurs de Hospital Universitario La Paz (36)

2023

  1. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study

    Neurologia, Vol. 38, Núm. 6, pp. 379-386

2022

  1. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494

  2. Epigenetic profiling linked to multisystem inflammatory syndrome in children (MIS-C): A multicenter, retrospective study

    eClinicalMedicine, Vol. 50

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. The Relationship between Angiogenic Factors and Energy Metabolism in Preeclampsia

    Nutrients, Vol. 14, Núm. 10

2021

  1. Epigenome-wide association study of COVID-19 severity with respiratory failure

    EBioMedicine, Vol. 66

  2. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  3. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery

    Clinical Therapeutics, Vol. 43, Núm. 5, pp. e86-e102

  4. Placental Compartmentalization of Lipid Metabolism: Implications for Singleton and Twin Pregnancies

    Reproductive Sciences, Vol. 28, Núm. 4, pp. 1150-1160

  5. SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?

    Journal of Experimental Medicine, Vol. 218, Núm. 6

2020

  1. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

  2. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects

    Clinical Drug Investigation, Vol. 40, Núm. 7, pp. 617-628

  3. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates

    Biomedicines, Vol. 8, Núm. 4

  4. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

2019

  1. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population

    International Journal of Antimicrobial Agents, Vol. 54, Núm. 4, pp. 463-470

2018

  1. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects

    Journal of Psychopharmacology, Vol. 32, Núm. 11, pp. 1212-1222

2017

  1. Parkinson's disease severity at 3 years can be predicted from non-motor symptoms at baseline

    Frontiers in Neurology, Vol. 8, Núm. OCT

  2. Prepregnancy body mass index influences lipid oxidation rate during pregnancy

    Acta Obstetricia et Gynecologica Scandinavica, Vol. 96, Núm. 2, pp. 207-215

  3. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

    Nature Genetics, Vol. 49, Núm. 9, pp. 1373-1384

2016

  1. Tissue specific expression of human fatty acid oxidation enzyme genes in late pregnancy

    Lipids in Health and Disease, Vol. 15, Núm. 1, pp. 1-5